linjc16/ctgov huggingface dataset:
HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma

Study Overview
=================
Brief Summary
-----------------
This study aims to analyze the multi-omics results between uterine cervical adenocarcinoma patients with and without human papillomavirus (HPV) infections. The multi-omics profiles include genome wide association study (GWAS), whole exome sequencing, analysis of transcriptomics and metabolomics. The HPV integration status is interpreted by GWAS. A comprehensive multi-omics will reveal the role of HPV integration in the molecular mechanism of tumorigenesis and prognosis of uterine cervical adenocarcinoma.

Official Title
-----------------
A Multi-omics Study on the Human Papillomavirus Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma

Conditions
-----------------
Cervical Adenocarcinoma, Human Papillomavirus, Genome-wide Association Study, Whole Exome Sequencing, Transcriptome, Metabolome, Tumorigenesis, Prognosis

Intervention / Treatment
-----------------
* Combination Product: A multi-omics analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed primary adenocarcinoma of the uterine cervix Signed an approved informed consents Feasible for biopsy Exclusion Criteria: Not meeting all of the inclusion criteria
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with HPV integration<br>The HPV integration status will be checked by GWAS. | Combination Product: A multi-omics analysis<br>* A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.<br>|
| Patients without HPV integration<br>The HPV integration status will be checked by GWAS. | Combination Product: A multi-omics analysis<br>* A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequencies of somatic driving mutations | The differences of frequencies of somatic driving mutations will be compared between patients with and without HPV integration. | Two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequencies of alteration of RNA expression | The alteration of patterns of RNA expression, including mRNA, miRNA, and lncRNA, will be compared between patients with and without HPV integration. | Two years | 
| Frequencies of alteration of protein expression and signal pathway | The alteration of patterns of protein expression and signal pathway will be compared between patients with and without HPV integration. | Two years | 
| Progression-free survival | Progression-free survival between patients with differential expressed multi-omics will be compared. | Five years |
IV Cocaine Abuse: A Laboratory Model - 3

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effects of buprenorpine on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving in non-opiate dependent cocaine users.

Official Title
-----------------
IV Cocaine Abuse: A Laboratory Model

Conditions
-----------------
Cocaine-Related Disorders

Intervention / Treatment
-----------------
* Drug: Buprenorphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Buprenorphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Direct cocaine effects (caridio, subjective) |  |  | 
| Interaction of coc/bup on cardio measures |  |  | 
| Ineraction of coc/bup on coc's subjective effects |  |  | 
| Effects of buprenorphine on cocaine craving |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intravenous abuse
Early Cardiac Extubation After Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
The management of heart valve disease is constantly evolving over time. The minimally invasive approach (mini-thoracotomy and J-hemisternotomy) is one of the major surgical evolutions. It has many advantages including, among others, a reduction of postoperative pain and the preservation of sternal stability This evolution of the surgical technique towards a less invasive approach encouraged the investigators to adapt the anesthetic management accordingly. In particular, immediate postoperative extubation appeared feasible. The investigators would therefore like to test the hypothesis that immediate extuation is non-inferior to delayed extubation with regard to patient safety. The investigators also investigated whether immediate extubation could be beneficiel in terms of vasopressors requirement, risk of early postoperative complications, fluid balance and length of stay in the intesive care unit and in the hopsital.

Official Title
-----------------
Early Cardiac Extubation After Cardiac Surgery: a Retrospective Single-center Non-inferiority Trial

Conditions
-----------------
Post-operative Cardiac Surgery

Intervention / Treatment
-----------------
* Procedure: Early extubation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Minimally invasive valve replacement intervention (thoracotomy or J-hemisternotomy) Exclusion Criteria: Combined surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Early extubated (in operating room) patients after valvular cardiac surgery<br> | Procedure: Early extubation<br>* Patients of the 2 groups are extubated at different moments: either immediately postoperatively, in the operating room, or after a few hours monitoring in ICU<br>|
| Later extubated (in ICU) patients after valvular cardiac surgery<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-operative complications | Intensive care unit length of stay (days) | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
post-operative complications, on table extubation
Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients

Study Overview
=================
Brief Summary
-----------------
The primary objective is to evaluate the antihypertensive efficacy of a fixed combination of Irbesartan/HydroChloroThiazide (CoAprovel) in Chinese moderate to severe hypertensive patients. The secondary objective is to get systolic blood pressure and diastolic blood pressure goal attainment rate from CoAprovel in Chinese hypertensive patients.

Official Title
-----------------
Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: irbesartan/hydrochlorothiazide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Essential hypertensive patients Moderate to severe Patients with uncontrolled blood pressure (systolic blood pressure ≥160mmHg, diastolic blood pressure ≥100mmHg for untreated, systolic blood pressure ≥150mmHg, diastolic blood pressure ≥95mmHg for treated on monotherapy). Patients are willing to discontinue previous antihypertensive medicine Exclusion Criteria: Pregnant or lactating women, or women of child bearing potential without contraceptive method. Hypersensitivity to any component of the products or other sulfonamide derived substances. Secondary hypertension. Severe renal impairment (Creatinine Clearance ≤30ml/min) Severe hepatic impairment, biliary cirrhosis and cholestasis. Refractory hypokalemia, hypercalcaemia. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: irbesartan/hydrochlorothiazide<br>* 50/12.5mg for 4 weeks follow 300/12.5mg for 4 weeks and proceed to 300/25mg for 4 weeks<br>* Other names: CoAprovel;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with controlled blood pressure |  | At month 3 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events |  | Throughout the study period | 
| Systolic and Diastolic Blood Pressure |  | At month 3 versus baseline |
A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.

Study Overview
=================
Brief Summary
-----------------
To assess the likelihood of keloid and scar formation, pigmentation disorders and hypersensitivity reactions in patients with skin of color undergoing correction of facial soft tissue contour deficiencies with Hylaform, Hylaform Plus or Captique.

Conditions
-----------------
Facial Wrinkles

Intervention / Treatment
-----------------
* Device: Hylaform, Hylaform Plus (hylan B gel)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: bilateral nasolabial folds with severity score 3 or 4 on the 6-point grading scale Exclusion Criteria: pregnant/lactating women patients who previously received permanent facial implants or using over-the-counter products

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Hylaform, Hylaform Plus (hylan B gel)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| no difference in keloid and scar formation |  |  | 
| pigmentation disorders |  |  | 
| hypersensitivity reactions in patients with skin color compared to other patients when treated for wrinkle correction with Hylaform, Hylaform Plus or Captique |  |  |
A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma

Study Overview
=================
Brief Summary
-----------------
This study collects and stores blood and tumor samples from patients with malignant melanoma and healthy individuals. The purpose of this study is to gain a better understanding of the causes of melanoma and how melanoma tumors behave. Storing blood and tumor samples for future research may lead to new discoveries that may ultimately help with diagnosing or treating this disease.

Detailed Description
-----------------
PRIMARY OBJECTIVE: I. Facilitate studies aimed at investigating new prognostic markers and potentially therapeutic therapies in malignant melanoma. OUTLINE: Patients undergo collection of blood samples at the time of the initial diagnostic work-up, and possibly prior to the initiation of surgery, chemotherapy, immunotherapy, or radiation therapy, at tumor progression or recurrence, and annually during routine follow-up (no more than 4 blood draws per year). Patients may also undergo collection of tissue sample during standard of care surgical or radiologic procedures. Healthy individuals undergo collection of blood samples up to 4 times over 1 year.

Official Title
-----------------
Analysis of the Tumor Microenvironment and Immune Response in Malignant Melanoma

Conditions
-----------------
Melanoma

Intervention / Treatment
-----------------
* Procedure: Biospecimen Collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with malignant melanoma or personal history of melanoma Normal donors Informed consent can be obtained Patients with any stage of malignant melanoma Exclusion Criteria: Incarcerated individuals will be excluded from this protocol
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ancillary-correlative (biospecimen collection)<br>Patients undergo collection of blood samples at the time of the initial diagnostic work-up, and possibly prior to the initiation of surgery, chemotherapy, immunotherapy, or radiation therapy, at tumor progression or recurrence, and annually during routine follow-up (no more than 4 blood draws per year). Patients may also undergo collection of tissue sample during standard of care surgical or radiologic procedures. Healthy individuals undergo collection of blood samples up to 4 times over 1 year. | Procedure: Biospecimen Collection<br>* Undergo collection of blood and tissue samples<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| New prognostic markers in malignant melanoma | Facilitate studies aimed at investigating new prognostic markers and potentially therapeutic therapies in malignant melanoma. . Draws conducted at baseline prior to immune therapy, four weeks after draw 1 and prior to the third cycle. | Up to 3 months |
Doppler Ultrasound in Characterization of Superficial Soft Tissue Masses

Study Overview
=================
Brief Summary
-----------------
A wide variety of superficial soft tissue masses may be seen in clinical practice. Superficial soft tissue masses can generally be categorized as mesenchymal tumors, skin appendage lesions, metastatic tumors, other tumors and tumor-like lesions, or inflammatory lesions. The investigators will use doppler ultrasound in evaluation of superficial soft tissue masses characterization.

Detailed Description
-----------------
There are many examples for these benign superficial soft tissue lesions as lipoma, ganglion, Baker's cyst, giant cell tumor, lymphangioma, hernia, abscess, epidermoid cyst, hematoma, muscle rupture, glomus tumor, fibromatosis, lymphadenitis hemangioma, exostosis, fibroma, neurofibroma and schwannoma. Malignant lesions also could be seen as lymphoma, metastasis, osteogenic sarcoma, liposarcoma , leiomyosarcoma, rhabdomyosarcoma and synovial sarcoma. Nowadays, High resolution ultrasound has a high sensitivity in detecting superficial soft tissue masses through the grey-scale grading that compose an image range from pure black at the weakest intensity to pure white at the strongest that can be used to evaluate its structure, some aspects of its function and to determine the nature of a mass lesion (cystic or solid) and with Doppler ultrasound which is an excellent imaging modality to determine the vascularity of superficial soft tissue masses that can be characterized in terms of their echogenicity, margin, shape, composition, acoustic transmission, size, the grading of color Doppler ultrasound , and resistive index in spectral Doppler as spectral Doppler will be applied in lesions with positive color flow signals.

Official Title
-----------------
Role of Doppler Ultrasound in Evaluation of Superficial Soft Tissue Masses

Conditions
-----------------
Mass of Soft Tissue

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients in different age groups with superficial soft tissue lesions Exclusion Criteria: If the patient undergo previous operations at the same mass that could change the criteria of that mass or if the mass is recurrent at the same site.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients diagnosed as superficial soft tissue lesions by doppler ultrasound. | Effectiveness of Doppler ultrasound in evaluation of superficial soft tissue masses in comparison with histopathological data of these lesions. | 2 years |
Effect of Hyaluronidase on Intraocular Pressure

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate effect of retrobulbar local anaesthesia after addition of hyaluronidase on IOP during cataract surgery

Official Title
-----------------
Effect of Hyaluronidase on Intraocular Pressure After Retrobulbar Anaesthesia During Cataract Surgery

Conditions
-----------------
Intraocular Pressure Low

Intervention / Treatment
-----------------
* Drug: Hyaluronidase


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1-Patients above the age of 50 years. 2-Patients with age related cataract. 3-Normal IOP. Exclusion Criteria: 1History of trauma. 2-Patients with glaucoma. 3-Previous ocular surgery. 4-Patients with other ocular pathology. 5-Uncontrolled diabetes or hypertension. 6-hypersensitivity to lignocaine. 7-Uncooperative or epileptic patients.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Effect of hyaluronidase on IOP<br> | Drug: Hyaluronidase<br>* 4ml of retrobulbar LA with addition of 15IU/ml hyaluronidase to 2% lidocaine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| reduction in IOP | reduction of complications of high IOP during surgery | within 10minutes |
Ultrasound Evaluation of Labor Epidural

Study Overview
=================
Brief Summary
-----------------
To compare the labor epidural analgesic (EA) profiles between landmark insertion EA levels which are congruent and ingruent to ultrasound confirmation in lateral decubitus position.

Detailed Description
-----------------
Epidural analgesia is the mainstream method for labor analgesia. Landmark identification of L3 to L5 spinous process is most commonly applied for determination of epidural insertion. However, the precision of epidural catheter insertion site was affected by physiological and anatomical variations in pregnant women and positions such as sitting or lateral decubitus. Previous study showed the clinical estimation would be ≥ 1 vertebral level higher than the anatomical position determined by ultrasound at least 40% of the time in sitting position among western pregnant women. For asian parturients, epidural analgesia is commonly performed in lateral decubitus position because of smaller stature. In addition, it remains uncertain whether the landmark epidural insertion level congruent or ingruent is associated with different analgesia profiles such as the dosage requirement and the frequncy of adjustment.

Official Title
-----------------
The Use of Ultrasound to Evaluate Precision and Analgesic Efficacy of Labor Epidural Analgesia

Conditions
-----------------
Parturient

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: Normal spontaneous delivery parturients receiving labor epidural analgesia in first stage of labor Using patient-controlled epidural analgesia Exclusion: who has an accidental epidural puncture who receives epidural insertion by ultrasound identification who uses of magnesium sulfate

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of landmark epidural level | Validation of landmark localization of epidural insertion level by using ultrasound examination | 10 minute | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Labor analgesic dose | Influences of accurate epidural insertion level on labor epidural analgesic dose | one day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
labor epidural, ultrasound